CA2351049C - Procede pour separer des nucleosides cis-1,3-oxathiolaniques recherches de leurs isomeres trans non desires - Google Patents

Procede pour separer des nucleosides cis-1,3-oxathiolaniques recherches de leurs isomeres trans non desires Download PDF

Info

Publication number
CA2351049C
CA2351049C CA002351049A CA2351049A CA2351049C CA 2351049 C CA2351049 C CA 2351049C CA 002351049 A CA002351049 A CA 002351049A CA 2351049 A CA2351049 A CA 2351049A CA 2351049 C CA2351049 C CA 2351049C
Authority
CA
Canada
Prior art keywords
cis
trans
acid
nucleoside
isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002351049A
Other languages
English (en)
Other versions
CA2351049A1 (fr
Inventor
K.S. Keshava Murthy
Gurijala V. Reddy
Zhi-Xian Wang
Chandrawansha B.W. Senanayake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apotex Pharmachem Inc
Original Assignee
Apotex Pharmachem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Pharmachem Inc filed Critical Apotex Pharmachem Inc
Publication of CA2351049A1 publication Critical patent/CA2351049A1/fr
Application granted granted Critical
Publication of CA2351049C publication Critical patent/CA2351049C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002351049A 2001-06-18 2001-06-18 Procede pour separer des nucleosides cis-1,3-oxathiolaniques recherches de leurs isomeres trans non desires Expired - Fee Related CA2351049C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/881,705 US6600044B2 (en) 2001-06-18 2001-06-18 Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
US09/881,705 2001-06-18

Publications (2)

Publication Number Publication Date
CA2351049A1 CA2351049A1 (fr) 2002-12-18
CA2351049C true CA2351049C (fr) 2007-03-13

Family

ID=25379023

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002351049A Expired - Fee Related CA2351049C (fr) 2001-06-18 2001-06-18 Procede pour separer des nucleosides cis-1,3-oxathiolaniques recherches de leurs isomeres trans non desires

Country Status (2)

Country Link
US (1) US6600044B2 (fr)
CA (1) CA2351049C (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1503796B (zh) * 2001-03-01 2012-07-04 三角药品公司 顺-ftc的多晶型物及其它晶型
US7501514B1 (en) * 2003-10-15 2009-03-10 Shire Biochem, Inc. Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides
EP1687735A4 (fr) * 2003-11-21 2007-02-14 Optive Res Inc Systeme et procede fournissant une representation structurale canonique de composes chimiques
US7968703B2 (en) 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
WO2006096954A1 (fr) * 2005-03-14 2006-09-21 Shire Biochem Inc. Procedes de preparation du cis-2-hydroxymethyl-4-(cytosin-1’-yl)-1,3-oxathiolane optiquement actif ou de sels de celui-ci acceptables sur le plan pharmaceutique
EP2086955A2 (fr) * 2006-10-30 2009-08-12 Lupin Ltd. Procédé amélioré de fabrication de lamivudine
KR100840495B1 (ko) * 2007-04-13 2008-06-23 한미약품 주식회사 라미부딘을 입체선택적으로 제조하는 방법
US8350030B2 (en) * 2007-12-07 2013-01-08 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2R, 5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
WO2010067375A2 (fr) 2008-12-08 2010-06-17 Hetero Research Foundation Résolution optique de nucléosides 1,3-oxathiolane substitués
CN102167696B (zh) * 2010-02-25 2013-09-18 南京正大天晴制药有限公司 拉米夫定草酸盐及其制备方法
WO2011141805A2 (fr) 2010-05-14 2011-11-17 Lupin Limited Procédé de production amélioré de lamivudine
CN103282369A (zh) 2011-04-08 2013-09-04 劳乐斯实验室私营有限公司 抗逆转录病毒化合物与抗氧化酸的固体形式、其制备方法以及其药物组合物
WO2014124006A1 (fr) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticules pour le suivi de l'imagerie par résonance magnétique et procédés de fabrication et d'utilisation associés
US9688666B2 (en) 2013-02-07 2017-06-27 Tobira Therapeutics, Inc. Lamivudine salts
KR20170106460A (ko) 2015-01-27 2017-09-20 더 존스 홉킨스 유니버시티 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
CN105646625B (zh) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 一种卡培他滨的制备方法
GB201610327D0 (en) * 2016-06-14 2016-07-27 Univ Nelson Mandela Metropolitan Process for producing Lamivudine and Entricitabine
CN106496208A (zh) * 2016-10-19 2017-03-15 上海博志研新药物技术有限公司 恩曲他滨的制备方法
US11498933B2 (en) 2017-03-31 2022-11-15 The John Hopkins University Prodrug compositions
EP3641929A2 (fr) 2017-06-19 2020-04-29 Massachusetts Institute Of Technology Procédés automatisés de synthèse et de modification de biopolymères enzymatiques parallélisées et évolutives à l'aide de dispositifs microfluidiques

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
AU4973293A (en) 1992-09-04 1994-03-29 University Of Birmingham, The Anomerisation process
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
RU2244712C2 (ru) 1998-08-12 2005-01-20 Гайлид Сайенсиз, Инк. Способ получения 1,3-оксатиоланового нуклеозида, способ получения производного 1,3-оксатиоланил-5-она
CA2308559C (fr) * 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones utiles pour la preparation d'analogues de nucleosides antiviraux

Also Published As

Publication number Publication date
CA2351049A1 (fr) 2002-12-18
US6600044B2 (en) 2003-07-29
US20030013880A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
CA2351049C (fr) Procede pour separer des nucleosides cis-1,3-oxathiolaniques recherches de leurs isomeres trans non desires
US6927291B2 (en) Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides
JP3292830B2 (ja) ２−ヒドロキシメチル−５−（５−フルオロシトシン−１ −イル）−１，３−オキサチオランの抗ウィルス活性および分割
CA2143107C (fr) .beta.-d-dioxolane-nucleosides, enantiomeres purs
US6525191B1 (en) Conformationally constrained L-nucleosides
US5852027A (en) Antiviral 1,3-dioxolane nucleoside analogues
EP0526253B1 (fr) Analogues de 1,3-oxathiolane nucléoside
US5248776A (en) Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
AU2002255654A1 (en) Method for the synthesis of 2',3'-dideoxy -2',3'-didehydronucleosides
EP1104415B1 (fr) Methode de production de nucleosides de 1,3-oxathiolane
CZ309696A3 (en) Diastereoselective process for preparing nucleoside analogs
WO1994004154A9 (fr) NUCLEOSIDES ENANTIOMERIQUEMENT PURS DE β-D-DIOXOLANE
KR20060008297A (ko) 2'-데옥시-β-Ｌ-뉴클레오시드의 제조방법
EP2225232B1 (fr) Procédé de préparation de 1,3-oxathiolanes substitués
CN114456169B (zh) 3′-脱氧-3′,4′-二脱氢核糖核苷类似物及其制备方法
JP2006504703A (ja) １，３−ジオキソランヌクレオシドの調製方法
WO2003087119A1 (fr) Procede de synthese de $g(b)-l-5-fluoro-2',3'-dideoxy-2',3'-didehydrocytidine ($g(b)-l-fd4c)
AU2008201984B2 (en) Antiviral activity and resolution of 2-hydroxymethyl-5-(5-flurocytosin-1-yl)-1,3-oxathiolane
WO2003010179A1 (fr) Procede de preparation de 2'-3'-dideoxy-2',3'-didehydro-nucleosides

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140618